Literature DB >> 11401314

Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women.

C Clavel1, M Masure, J P Bory, I Putaud, C Mangeonjean, M Lorenzato, P Nazeyrollas, R Gabriel, C Quereux, P Birembaut.   

Abstract

High-risk human papillomaviruses (HR-HPV) are the necessary cause of cervical carcinomas. To determine whether HPR-HPV DNA detection in primary routine screening could represent a sensitive and reliable technique for the detection of high-grade squamous intraepithelial lesions (HGSIL), laboratory analysis using 2 cytologic techniques (conventional and liquid-based), HPV testing with Hybrid Capture II assay (HC-II), followed by colposcopic examination of women with abnormal cervical finding and/or persistent HR-HPV infection, was conducted in 7932 women who had routine cervical examination. The sensitivity of HPV testing for detecting a histologically proven HGSIL was 100%, higher than that of conventional (68.1%) and liquid-based (87.8%) cytology. The low specificities of 85.6% and 87.3% of HPV testing slightly increased to 88.4% and 90.1% if HPV testing was reserved for woman >30 years old. The quantitative approach provided by the HC-II assay for the assessment of the viral load was not reliable for predicting HGSIL in normal smears. HR-HPV testing could be proposed in primary screening in association with cytology. With conventional cytology it significantly improves the detection of HGSIL. With the use of the same cervical scrape for HPV testing and liquid-based cytology, HR-HPV testing would allow to select positive samples treated in a second time for cytology which gives a good specificity. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401314      PMCID: PMC2363679          DOI: 10.1054/bjoc.2001.1845

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  40 in total

1.  HPV typing and testing in gynaecological pathology: has the time come?

Authors:  C J Meijer; T J Helmerhorst; L Rozendaal; J C van der Linden; F J Voorhorst; J M Walboomers
Journal:  Histopathology       Date:  1998-07       Impact factor: 5.087

2.  Evaluation of the ThinPrep Pap test in clinical practice. A seven-month, 16,314-case experience in northern Vermont.

Authors:  J L Papillo; M A Zarka; T L St John
Journal:  Acta Cytol       Date:  1998 Jan-Feb       Impact factor: 2.319

3.  Human papillomavirus DNA testing for cervical cancer screening in low-resource settings.

Authors:  L Kuhn; L Denny; A Pollack; A Lorincz; R M Richart; T C Wright
Journal:  J Natl Cancer Inst       Date:  2000-05-17       Impact factor: 13.506

Review 4.  Is human papillomavirus testing of value in clinical practice?

Authors:  R H Kaufman; E Adam
Journal:  Am J Obstet Gynecol       Date:  1999-05       Impact factor: 8.661

5.  A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types.

Authors:  K L Liaw; A Hildesheim; R D Burk; P Gravitt; S Wacholder; M M Manos; D R Scott; M E Sherman; R J Kurman; A G Glass; S M Anderson; M Schiffman
Journal:  J Infect Dis       Date:  2000-11-16       Impact factor: 5.226

6.  Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer.

Authors:  E L Franco; L L Villa; J P Sobrinho; J M Prado; M C Rousseau; M Désy; T E Rohan
Journal:  J Infect Dis       Date:  1999-11       Impact factor: 5.226

7.  A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection.

Authors:  L A Koutsky; K K Holmes; C W Critchlow; C E Stevens; J Paavonen; A M Beckmann; T A DeRouen; D A Galloway; D Vernon; N B Kiviat
Journal:  N Engl J Med       Date:  1992-10-29       Impact factor: 91.245

8.  Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia.

Authors:  G Y Ho; R D Burk; S Klein; A S Kadish; C J Chang; P Palan; J Basu; R Tachezy; R Lewis; S Romney
Journal:  J Natl Cancer Inst       Date:  1995-09-20       Impact factor: 13.506

9.  Is human papillomavirus testing an effective triage method for detection of high-grade (grade 2 or 3) cervical intraepithelial neoplasia?

Authors:  E Adam; R H Kaufman; Z Berkova; J Icenogle; W C Reeves
Journal:  Am J Obstet Gynecol       Date:  1998-06       Impact factor: 8.661

10.  Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women.

Authors:  C Clavel; M Masure; J P Bory; I Putaud; C Mangeonjean; M Lorenzato; R Gabriel; C Quereux; P Birembaut
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

View more
  59 in total

1.  Method for testing for human papillomavirus infection in patients with cervical intraepithelial disease.

Authors:  Hsing-Pei Lin; Yang-Yang Huang; Hsueh-Yin Wu; Jau-Tsuen Kao
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

2.  The advantages of incorporating liquid-based cytology (TACAS™) in mass screening for cervical cancer.

Authors:  Yoshihito Yokoyama; Masayuki Futagami; Jun Watanabe; Atsushi Sakuraba; Kazuma Nagasawa; Hidetoshi Maruyama; Shigemi Sato
Journal:  Hum Cell       Date:  2016-01-06       Impact factor: 4.174

3.  Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types.

Authors:  Tarik Gheit; Stefano Landi; Federica Gemignani; Peter J F Snijders; Salvatore Vaccarella; Silvia Franceschi; Federico Canzian; Massimo Tommasino
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

4.  Implementation of human papillomavirus testing in cervical screening without a concomitant decrease in participation rate.

Authors:  N W J Bulkmans; S Bulk; M S Ottevanger; L Rozendaal; S M Hellenberg; F J van Kemenade; P J F Snijders; A J P Boeke; C J L M Meijer
Journal:  J Clin Pathol       Date:  2006-08-30       Impact factor: 3.411

5.  Validation of a low-cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranes.

Authors:  C Estrade; P-A Menoud; D Nardelli-Haefliger; R Sahli
Journal:  J Clin Microbiol       Date:  2011-08-10       Impact factor: 5.948

6.  Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial.

Authors:  A Sargent; A Bailey; A Turner; M Almonte; C Gilham; H Baysson; J Peto; C Roberts; C Thomson; M Desai; J Mather; H Kitchener
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

7.  Study of viral integration of HPV-16 in young patients with LSIL.

Authors:  G Gallo; M Bibbo; L Bagella; A Zamparelli; F Sanseverino; M R Giovagnoli; A Vecchione; A Giordano
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

8.  Prediction of high-grade squamous intraepithelial lesions using the modified Reid index.

Authors:  Dae G Hong; Won J Seong; Sung Y Kim; Yoon S Lee; Young L Cho
Journal:  Int J Clin Oncol       Date:  2010-01-20       Impact factor: 3.402

9.  Optimizing technology for cervical cancer screening in high-resource settings.

Authors:  Lyndsay A Richardson; Joseph Tota; Eduardo L Franco
Journal:  Expert Rev Obstet Gynecol       Date:  2011-05

10.  The laboratory diagnosis of genital human papillomavirus infections.

Authors:  François Coutlée; Danielle Rouleau; Alex Ferenczy; Eduardo Franco
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-03       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.